Leerink Partnrs Has Bearish Estimate for Insulet Q4 Earnings

Insulet Co. (NASDAQ:PODD) – Stock analysts at Leerink Partnrs dropped their Q4 2024 earnings per share estimates for shares of Insulet in a research report issued to clients and investors on Thursday, November 7th. Leerink Partnrs analyst M. Kratky now anticipates that the medical instruments supplier will earn $0.99 per share for the quarter, down from their prior estimate of $1.00. The consensus estimate for Insulet’s current full-year earnings is $3.10 per share. Leerink Partnrs also issued estimates for Insulet’s Q2 2025 earnings at $0.88 EPS, Q3 2025 earnings at $1.15 EPS, Q4 2025 earnings at $1.22 EPS, FY2027 earnings at $6.46 EPS and FY2028 earnings at $7.75 EPS.

Insulet (NASDAQ:PODD) last posted its earnings results on Thursday, August 8th. The medical instruments supplier reported $0.55 EPS for the quarter, missing analysts’ consensus estimates of $0.56 by ($0.01). The firm had revenue of $488.50 million for the quarter, compared to the consensus estimate of $488.00 million. Insulet had a net margin of 21.22% and a return on equity of 30.29%. The firm’s revenue was up 23.2% compared to the same quarter last year. During the same quarter in the prior year, the company posted $0.38 earnings per share.

Several other analysts have also weighed in on PODD. UBS Group increased their price target on Insulet from $211.00 to $223.00 and gave the company a “neutral” rating in a report on Friday, August 9th. Barclays increased their price target on Insulet from $200.00 to $220.00 and gave the company an “equal weight” rating in a report on Monday, August 12th. Piper Sandler increased their price target on Insulet from $230.00 to $285.00 and gave the company an “overweight” rating in a report on Tuesday, September 17th. Sanford C. Bernstein initiated coverage on Insulet in a report on Wednesday, November 6th. They set an “outperform” rating and a $300.00 price target on the stock. Finally, Canaccord Genuity Group increased their price target on Insulet from $236.00 to $269.00 and gave the company a “buy” rating in a report on Wednesday, September 25th. Three analysts have rated the stock with a hold rating and twelve have issued a buy rating to the stock. According to data from MarketBeat.com, the stock has an average rating of “Moderate Buy” and a consensus target price of $246.80.

Insulet Stock Up 9.4 %

NASDAQ PODD opened at $268.00 on Monday. The stock has a 50 day moving average price of $232.01 and a 200-day moving average price of $204.48. Insulet has a one year low of $151.56 and a one year high of $275.52. The company has a market capitalization of $18.79 billion, a P/E ratio of 45.89, a P/E/G ratio of 5.00 and a beta of 1.22. The company has a debt-to-equity ratio of 1.36, a quick ratio of 2.71 and a current ratio of 3.60.

Hedge Funds Weigh In On Insulet

A number of hedge funds and other institutional investors have recently made changes to their positions in the company. Wedmont Private Capital grew its position in shares of Insulet by 3.5% during the 3rd quarter. Wedmont Private Capital now owns 1,433 shares of the medical instruments supplier’s stock worth $326,000 after buying an additional 48 shares in the last quarter. OVERSEA CHINESE BANKING Corp Ltd boosted its position in Insulet by 4.7% during the third quarter. OVERSEA CHINESE BANKING Corp Ltd now owns 1,076 shares of the medical instruments supplier’s stock valued at $250,000 after purchasing an additional 48 shares in the last quarter. Blue Trust Inc. boosted its position in Insulet by 84.1% during the third quarter. Blue Trust Inc. now owns 127 shares of the medical instruments supplier’s stock valued at $30,000 after purchasing an additional 58 shares in the last quarter. Sumitomo Mitsui DS Asset Management Company Ltd boosted its position in Insulet by 1.1% during the second quarter. Sumitomo Mitsui DS Asset Management Company Ltd now owns 6,265 shares of the medical instruments supplier’s stock valued at $1,264,000 after purchasing an additional 66 shares in the last quarter. Finally, Greenleaf Trust boosted its position in Insulet by 4.2% during the third quarter. Greenleaf Trust now owns 1,783 shares of the medical instruments supplier’s stock valued at $415,000 after purchasing an additional 72 shares in the last quarter.

About Insulet

Insulet Corporation develops, manufactures, and sells insulin delivery systems for people with insulin-dependent diabetes. The company's Omnipod platform includes the Omnipod 5 Automated Insulin Delivery System (Omnipod 5) which includes a proprietary AID algorithm embedded in the Pod that integrates with a third-party continuous glucose monitor to obtain glucose values through wireless bluetooth communication; Omnipod DASH that features a bluetooth enabled Pod that is controlled by a smartphone-like Personal Diabetes Manager with a color touch screen user interface; and Omnipod GO, a standalone, wearable, insulin delivery system that provides a fixed rate of continuous rapid-acting insulin for 72 hours.